A Phase 1 interventional study of Brexpiprazole 1mg to 4mg in Schizophrenia, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2016-02-04.
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies testing brexpiprazole in Schizophrenia — 1 open to participants now, 1 under way, none of them phase 3. brexpiprazole · Schizophrenia.
Among the 28 studies testing brexpiprazole in Schizophrenia, this one is the 27th largest by enrollment, is one of 6 that started in 2013, is one of 8 in phase 1, and was the 15th registered.
3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.
Browse Schizophrenia studies →1 of the 28 studies testing brexpiprazole in Schizophrenia is open now. Recruiting first, the newest first:
New York State Psychiatric Institute
Ages 18–55
brexpiprazole: first FDA approval 2015 (REXULTI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 45 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 3 · Phase 3 17 · Phase 4 1
First in 2008; this study’s year is marked. 6 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 12 is below the median of 70 across 2,951 interventional studies indexed under Schizophrenia.
Median enrollment 155 across the 28 interventional studies. Of the 26 that completed or were terminated, 22 (85%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 28 have an industry lead sponsor. The 7 most frequent:
This study is registered under Otsuka Pharmaceutical Development & Commercialization, Inc., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Otsuka Pharmaceutical Development & Commercialization, Inc. is the lead sponsor of 297 studies on the registry; 19 are open to participants now.
Of its 106 completed or terminated interventional studies of FDA-regulated products, 71 (67%) have results posted.
120 studies in Schizophrenia by Otsuka Holdings Co., Ltd.: 3 open now, 4 under way, 3 of them phase 3. Of 111 finished, 64 (58%) have results posted.
Among the 120 studies in Schizophrenia by Otsuka Holdings Co., Ltd., this one is the 105th largest by enrollment of the 111 interventional ones that give a count, is one of 9 that started in 2013, is one of 34 in phase 1, and was the 52nd registered.
Otsuka Holdings Co., Ltd.’s Schizophrenia studies by the year they started, since 1998.
None of the studies under way reaches primary completion within a year.
Among the 28 studies testing brexpiprazole in Schizophrenia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Otsuka Holdings Co., Ltd.’s 120 in Schizophrenia:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine how low and high does of brexpiprazole binds to certain receptors in the brain. This will be determined by PET scans taken pre-dose and post-dose.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
History of or current hepatitis or acquired immunodeficiency syndrome or carriers of and/or anti- or antibodies.
The following laboratory test, vital sign, and results are exclusionary:
Antipsychotics
Anxiolytics and Sleep Aids
Mood Stabilizers
Selective Serotonin Reuptake Inhibitors
Serotonin and Norepinephrine Reuptake Inhibitors
Other
Additionally, subjects who meet the following imaging exclusion criteria will not be included in this trial:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Three cohorts of subjects will be evaluated: - Cohorts 1 and 3 will receive high doses of brexpiprazole, and Cohort 2 will receive low doses of brexpiprazole.
Drug: Brexpiprazole 1mg to 4mg
Also known as: Brexpiprazole
Change in Percentage Dopamine D2/D3 Receptor Occupancy
Dopamine receptor occupancy measured using the radiotracer \[11C\]-(+)-PHNO in low and high dose. The binding of brexpiprazole to the D2/D3 receptors were assessed by comparing the binding potential from the Baseline scan (prior to treatment) to that of Day 10 (after treatment). The D2/D3 receptors following administration of a 1- and 4-mg doses of brexpiprazole were assessed and the occupancy estimates were averaged across brain regions 4 hours post-last dose on Day 10.
Time frame: Baseline to 4 hours post-last dose on Day 10
Change in Percentage 5-HT1A Receptor Occupancy
Mean (±SD) Serotonin 5-HT1A Receptor Occupancy Using the Radiotracer \[11C\]CUMI101 in high dose only. In cohorts 1, 2 and 3, the binding of brexpiprazole to the 5-HT1A receptors was assessed by comparing the binding potential from the Baseline scan (prior to treatment) to that of Day 10 (after treatment). The 5-HT1A receptors following administration of a 4-mg dose of brexpiprazole was assessed and the occupancy estimates were averaged across brain regions 4 hours post-last dose on Day 10.
Time frame: Baseline to 4 hours post-last dose on Day 10
Change in Percentage 5-HT2A Receptor Occupancy
Mean (±SD) Serotonin 5-HT2A Receptor Occupancy Using the Radiotracer \[11C\]MDL100907 (in low and high dose). The 5-HT2A receptors following administration of 1- and 4-mg doses of brexpiprazole were assessed and the occupancy estimates were averaged across brain regions 4 hours post-last dose on Day 10.
Time frame: Baseline and 4 hours post-last dose on Day 10
Change in Occupancy at Serotonin Transporter (SERT)
Mean (±SD) SERT Occupancy Using the Radiotracer \[11C\]DASB in high dose only. Occupancy estimates were averaged across brain regions 4 hours post-last dose.
Time frame: Baseline to 4 hours post-last dose on Day 10
Area Under the Concentration-time Curve (AUCτ) During a Dosing Interval at Steady-state for Brexpiprazole and Its Metabolite DM-3411
AUC during a dosing interval at steady-state for brexpiprazole and its metabolite DM-3411. Days 1 and 9: predose (within 15 minutes prior to dosing) Day 10: predose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 8, and 12 hours post-last dose.
Time frame: Baseline to Day 10
Peak (Maximal) Concentration of Drug in Plasma (Cmax) for Brexpiprazole and Its Metabolite DM-3411
(Cmax) Days 1 and 9: predose (within 15 minutes prior to dosing) Day 10: predose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 8, and 12 hours post-last dose.
Time frame: Baseline to Day 10
Apparent Clearance of Drug From Plasma After Extravascular Administration (CL/F; Only Brexpiprazole)
PK parameter - CL/F was assessed for brexpiprazole only. Days 1 and 9: predose (within 15 minutes prior to dosing) Day 10: predose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 8, and 12 hours post-last dose.
Time frame: Baseline to Day 10
Time to Maximum (Peak) Plasma Concentration (Tmax) for Brexpiprazole and Its Metabolite DM-3411
Tmax for brexpiprazole and its metabolite DM-3411. Days 1 and 9: predose (within 15 minutes prior to dosing) Day 10: predose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 8, and 12 hours post-last dose.
Time frame: Baseline to Day 10
Mean Change From Baseline in Abnormal Involuntary Movement Scale (AIMS) Score
The AIMS Scale was an extrapyramidal symptoms (EPS) rating scale. The AIMS is a 12 item scale. The first 10 items e.g. facial and oral movements (items 1-4), extremity movements (items 5 and 6), trunk movements (item 7), investigators global assessment of dyskinesia (items 8 to 10). The first 10 items are rated from 0 to 4 (0=best, 4=worst). Items 11 and 12, related to dental status, have dichotomous responses, 0=no and 1=yes. The AIMS Total Score is the sum of the ratings for the first seven items. The possible total scores are from 0 to 28, with a higher score indicating worse outcome. Last Visit is the last scheduled post-baseline evaluation including early termination evaluation.
Time frame: Baseline to Day 6, 11 and Last Visit
Mean Change From Baseline in Simpson-Angus Scale (SAS) Total Score
The SAS is a rating scale used to measure EPS. The SAS scale consists of a list of 10 symptoms of parkinsonism (gait, arm dropping, shoulder shaking, elbow rigidity, wrist rigidity, head rotation, glabella tap, tremor, salivation, and akathisia), with each item rated from 0 to 4, with 0 being normal and 4 being the worst. The SAS Total score is sum of ratings for all 10 items, with possible Total scores from 0 to 40, with higher scores indicating worse outcome. Last Visit is the last scheduled post-baseline evaluation including early termination evaluation.
Time frame: Baseline to Day 6, 11 and Last Visit
Mean Change From Baseline in Barnes Akathisia Rating Scale (BARS) Score
The BARS consisted of 4 items related to akathisia: objective observation of akathisia by the study physician, subjective feelings of restlessness by the participant, participant distress due to akathisia, and global evaluation of akathisia. The first 3 items were rated on a 4-point scale, with a score of 0 = absence of symptoms and a score of 3 = severe condition. The global clinical evaluation were made on a 6-point scale, (0=absent, 1=questionable, 2=mild, 3=moderate, 4=marked, 5=severe). To complete this scale, participants were observed while they were seated and then stood for a minimum of 2 minutes in each position. Symptoms observed in other situations (e.g., while engaged in neutral conversation or engaged in activity on the ward) may also be rated. Subjective phenomena were to be elicited by direct questioning. The BARS total score (when combined) ranged from 0 to 18, with higher values indicating a severe condition.
Time frame: Baseline to Day 6, 11 and Last Visit
Percentage of Participants Who Reported at Least One Occurrence of Suicidality, Suicidal Behavior and Suicidal Ideation on the Columbia-Suicide Severity Rating Scale (C-SSRS)
The C-SSRS captures the occurrence, severity, and frequency of suicide-related thoughts and behaviors during the assessment period. Suicidality was defined as reporting at least one occurrence of any suicidal behavior or suicidal ideation. Suicidal behavior was defined as reporting any type of suicidal behaviors (actual attempt, interrupted attempt, aborted attempt, and preparatory acts or behavior). The suicidal ideation intensity total score is the sum of intensity scores of 5 items (frequency, duration, controllability, deterrents, and reasons for ideation). The score of each intensity item ranges from 0 (none) to 5 (worst) which leads to the range of the total score from 0 to 25, with a higher score indicating a worse outcome. A missing score of any item resulted in a missing total score. If no suicidal ideation was reported, a score of 0 was given to the intensity scale. Last Visit is last scheduled post-baseline evaluation including early termination evaluation.
Time frame: Baseline to Last Visit
Mean Change From Baseline in Positive and Negative Symptom Scale (PANSS) Total Score
The PANSS consisted of three subscales: a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) and a score of 7 (extremely severe symptoms). The PANSS total score was the sum of the rating scores for 7 positive scale items, 7 negative scale items, and 16 general psychopathology scale items from the PANSS panel. The PANSS total score ranged from 30 (best possible outcome) to 210 (worst possible outcome). Last Visit is the last scheduled post-baseline evaluation including early termination evaluation.
Time frame: Baseline to Day 6, 11 and Last Visit
Mean Change From Baseline in PANNS Positive Subscale Score
The PANSS consisted of three subscales: a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) and a score of 7 (extremely severe symptoms). The PANSS positive subscale score was the sum of the rating scores for the 7 positive scale items from the PANSS panel. The 7 positive symptom constructs are delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution, and hostility. The PANSS Positive Subscale ranges from 7 (absence of symptoms) to 49 (extremely severe symptoms). Last Visit is the last scheduled post-baseline evaluation including early termination evaluation.
Time frame: Baseline to Day 6, 11 and Last Visit
Mean Change From Baseline in PANSS Negative Subscale Score
The PANSS consisted of three subscales: a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) and a score of 7 (extremely severe symptoms). The PANSS negative subscale score was the sum of the rating scores for the 7 negative scale items from the PANSS panel. The 7 negative symptom constructs: blunted affect, emotional withdrawal, poor rapport, passive apathetic withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation, stereotyped thinking. The PANSS Negative Subscale ranges from 7 (absence of symptoms) to 49 (extremely severe symptoms). Last Visit is the last scheduled post-baseline evaluation including early termination evaluation.
Time frame: Baseline to Day 6, 11 and Last Visit
Mean Change From Baseline in Clinical Global Impression-Severity (CGI-S) Score
The severity of illness for each participant was rated using the CGI-S scale. To assess CGI-S, the study physician answered the following question: "Considering your total clinical experience with this particular population, how mentally ill is the participant at this time?" Response choices included: 0 = not assessed; 1 = normal, not ill at all; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants. Last Visit is the last scheduled post-baseline evaluation including early termination evaluation.
Time frame: Baseline to Day 6, 11 and Last Visit
Mean Change From Baseline in Clinical Global Impression-Improvement (CGI-I) Score
The efficacy of trial medication were rated for each participant using the CGI-I scale. The study physician must rate the participant's total improvement whether or not it is due entirely to drug treatment. All responses were compared to the participant's condition at baseline. Response choices include: 0 = not assessed; 1 =very much improved; 2 = much improved; 3 = minimally improved; 4 = no change; 5 =minimally worse; 6 = much worse; and 7 = very much worse. Last Visit is the last scheduled post-baseline evaluation including early termination evaluation.
Time frame: Baseline to Day 6, 11 and Last Visit
A Phase 1, single center, open-label trial of up to 12 enrolled participants.
| Milestone | Cohort 1 - Brexpiprazole 4 mg | Cohort 2 - Brexpiprazole 1 mg | Cohort 3 - Brexpiprazole 4 mg |
|---|---|---|---|
| Started | 4 | 4 | 4 |
| Completed | 4 | 4 | 3 |
| Not completed | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 |
Dopamine receptor occupancy measured using the radiotracer \[11C\]-(+)-PHNO in low and high dose. The binding of brexpiprazole to the D2/D3 receptors were assessed by comparing the binding potential from the Baseline scan (prior to treatment) to that of Day 10 (after treatment). The D2/D3 receptors following administration of a 1- and 4-mg doses of brexpiprazole were assessed and the occupancy estimates were averaged across brain regions 4 hours post-last dose on Day 10.
| percentage occupancy | Brexpiprazole 1mg | Brexpiprazole 4 mg |
|---|---|---|
| 6-region model (D2 receptor) | 36 ± 16 | 59 ± 5 |
| 6-region model (D3 receptor) | 2 ± 3 | 13 ± 10 |
| 8-region model (D2 receptor) | 27 ± 25 | 67 ± 15 |
| 8-region model (D3 receptor) | 1 ± 2 | 31 ± 8 |
Mean (±SD) Serotonin 5-HT1A Receptor Occupancy Using the Radiotracer \[11C\]CUMI101 in high dose only. In cohorts 1, 2 and 3, the binding of brexpiprazole to the 5-HT1A receptors was assessed by comparing the binding potential from the Baseline scan (prior to treatment) to that of Day 10 (after treatment). The 5-HT1A receptors following administration of a 4-mg dose of brexpiprazole was assessed and the occupancy estimates were averaged across brain regions 4 hours post-last dose on Day 10.
| percentage occupancy | Brexpiprazole 4mg |
|---|---|
| Change in Percentage 5-HT1A Receptor Occupancy | 4 ± 6 |
Mean (±SD) Serotonin 5-HT2A Receptor Occupancy Using the Radiotracer \[11C\]MDL100907 (in low and high dose). The 5-HT2A receptors following administration of 1- and 4-mg doses of brexpiprazole were assessed and the occupancy estimates were averaged across brain regions 4 hours post-last dose on Day 10.
| percentage occupancy | Brexpiprazole 1mg | Brexpiprazole 4 mg |
|---|---|---|
| Change in Percentage 5-HT2A Receptor Occupancy | 28 ± 10 | 45 ± 7 |
Mean (±SD) SERT Occupancy Using the Radiotracer \[11C\]DASB in high dose only. Occupancy estimates were averaged across brain regions 4 hours post-last dose.
| percentage occupancy | Brexpiprazole 4mg |
|---|---|
| Change in Occupancy at Serotonin Transporter (SERT) | -3 ± 15 |
AUC during a dosing interval at steady-state for brexpiprazole and its metabolite DM-3411. Days 1 and 9: predose (within 15 minutes prior to dosing) Day 10: predose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 8, and 12 hours post-last dose.
| hr*ng/mL | Cohort 1 - Brexpiprazole 4mg | Cohort 2 - Brexpiprazole 1mg | Cohort 3 - Brexpiprazole 4 mg |
|---|---|---|---|
| Brexpiprazole | 2520 ± 1290 | 716 ± 118 | 1410 ± 352 |
| DM-3411 | 807 ± 205 | 329 ± 227 | 761 ± 397 |
(Cmax) Days 1 and 9: predose (within 15 minutes prior to dosing) Day 10: predose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 8, and 12 hours post-last dose.
| ng/mL | Cohort 1 - Brexpiprazole 4mg | Cohort 2- Brexpiprazole 1mg | Cohort 3 - Brexpiprazole 4mg |
|---|---|---|---|
| Brexpiprazole | 126 ± 58.3 | 46.5 ± 7.47 | 70.9 ± 18.8 |
| DM-3411 | 37.1 ± 10.8 | 17.3 ± 10.4 | 35.7 ± 18.6 |
PK parameter - CL/F was assessed for brexpiprazole only. Days 1 and 9: predose (within 15 minutes prior to dosing) Day 10: predose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 8, and 12 hours post-last dose.
| mL/hr | Cohort 1 - Brexpiprazole 4 mg | Cohort 2 - Brexpiprazole 1mg | Cohort 3 - Brexpiprazole 4mg |
|---|---|---|---|
| Apparent Clearance of Drug From Plasma After Extravascular Administration (CL/F; Only Brexpiprazole) | 1960 ± 960 | 1420 ± 242 | 2970 ± 831 |
Tmax for brexpiprazole and its metabolite DM-3411. Days 1 and 9: predose (within 15 minutes prior to dosing) Day 10: predose (within 15 minutes prior to dosing) and 1, 2, 3, 4, 5, 6, 8, and 12 hours post-last dose.
| hour | Cohort 1 - Brexpiprazole 4mg | Cohort 2 - Brexpiprazole 1mg | Cohort 3 - Brexpiprazole 4mg |
|---|---|---|---|
| Brexpiprazole | 1.92 (0.00 to 2.92) | 1.50 (0.93 to 1.93) | 4.87 (3.10 to 6.00) |
| DM-3411 | 2.42 (0.00 to 24.08) | 1.51 (0.00 to 11.92) | 11.87 (3.10 to 24.00) |
The AIMS Scale was an extrapyramidal symptoms (EPS) rating scale. The AIMS is a 12 item scale. The first 10 items e.g. facial and oral movements (items 1-4), extremity movements (items 5 and 6), trunk movements (item 7), investigators global assessment of dyskinesia (items 8 to 10). The first 10 items are rated from 0 to 4 (0=best, 4=worst). Items 11 and 12, related to dental status, have dichotomous responses, 0=no and 1=yes. The AIMS Total Score is the sum of the ratings for the first seven items. The possible total scores are from 0 to 28, with a higher score indicating worse outcome. Last Visit is the last scheduled post-baseline evaluation including early termination evaluation.
| Units on a scale | Cohort 1 - Brexpiprazole 4mg | Cohort 2 - Brexpiprazole 1mg | Cohort 3 Brexpiprazole 4mg |
|---|---|---|---|
| Day 6 | 0 ± 0 | 0 ± 0 | 0.3 ± 0.5 |
| Day 11 | 0 ± 0 | 0 ± 0 | 0 ± 0 |
| Last Visit | 0 ± 0 | 0 ± 0 | 0 ± 0 |
The SAS is a rating scale used to measure EPS. The SAS scale consists of a list of 10 symptoms of parkinsonism (gait, arm dropping, shoulder shaking, elbow rigidity, wrist rigidity, head rotation, glabella tap, tremor, salivation, and akathisia), with each item rated from 0 to 4, with 0 being normal and 4 being the worst. The SAS Total score is sum of ratings for all 10 items, with possible Total scores from 0 to 40, with higher scores indicating worse outcome. Last Visit is the last scheduled post-baseline evaluation including early termination evaluation.
| Units on scale | Cohort 1 - Brexpiprazole 4mg | Cohort 2- Brexpiprazole 1mg | Cohort 3 Brexpiprazole 4mg |
|---|---|---|---|
| Day 6 | 0.3 ± 0.5 | 0 ± 0 | -0.3 ± 1.3 |
| Day 11 | 0 ± 0 | 0 ± 0 | -0.7 ± 1.2 |
| Last Visit | 0 ± 0 | 0 ± 0 | -0.5 ± 1.0 |
The BARS consisted of 4 items related to akathisia: objective observation of akathisia by the study physician, subjective feelings of restlessness by the participant, participant distress due to akathisia, and global evaluation of akathisia. The first 3 items were rated on a 4-point scale, with a score of 0 = absence of symptoms and a score of 3 = severe condition. The global clinical evaluation were made on a 6-point scale, (0=absent, 1=questionable, 2=mild, 3=moderate, 4=marked, 5=severe). To complete this scale, participants were observed while they were seated and then stood for a minimum of 2 minutes in each position. Symptoms observed in other situations (e.g., while engaged in neutral conversation or engaged in activity on the ward) may also be rated. Subjective phenomena were to be elicited by direct questioning. The BARS total score (when combined) ranged from 0 to 18, with higher values indicating a severe condition.
| Units on a scale | Cohort 1 - Brexpiprazole 4mg | Cohort 2- Brexpiprazole 1mg | Cohort 3 Brexpiprazole 4mg |
|---|---|---|---|
| Day 6 | 0.5 ± 1.0 | 0 ± 0 | 0.5 ± 1.0 |
| Day 11 | 0.5 ± 1.0 | 0 ± 0 | 0.0 ± 0.0 |
| Last Visit | 0.5 ± 1.0 | 0 ± 0 | 0.0 ± 0.0 |
The C-SSRS captures the occurrence, severity, and frequency of suicide-related thoughts and behaviors during the assessment period. Suicidality was defined as reporting at least one occurrence of any suicidal behavior or suicidal ideation. Suicidal behavior was defined as reporting any type of suicidal behaviors (actual attempt, interrupted attempt, aborted attempt, and preparatory acts or behavior). The suicidal ideation intensity total score is the sum of intensity scores of 5 items (frequency, duration, controllability, deterrents, and reasons for ideation). The score of each intensity item ranges from 0 (none) to 5 (worst) which leads to the range of the total score from 0 to 25, with a higher score indicating a worse outcome. A missing score of any item resulted in a missing total score. If no suicidal ideation was reported, a score of 0 was given to the intensity scale. Last Visit is last scheduled post-baseline evaluation including early termination evaluation.
| Percentage of participants | Cohort 1 - Brexpiprazole 4mg | Cohort 2- Brexpiprazole 1mg | Cohort 3 Brexpiprazole 4mg |
|---|---|---|---|
| Suicidality | 0 | 0 | 0 |
| Suicidal behaviour | 0 | 0 | 0 |
| Suicidal Ideation | 0 | 0 | 0 |
The PANSS consisted of three subscales: a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) and a score of 7 (extremely severe symptoms). The PANSS total score was the sum of the rating scores for 7 positive scale items, 7 negative scale items, and 16 general psychopathology scale items from the PANSS panel. The PANSS total score ranged from 30 (best possible outcome) to 210 (worst possible outcome). Last Visit is the last scheduled post-baseline evaluation including early termination evaluation.
| Units on a scale | Cohort 1 - Brexpiprazole 4mg | Cohort 2 - Brexpiprazole 1mg | Cohort 3 - Brexpiprazole 4mg |
|---|---|---|---|
| Day 6 | -4.0 ± 7.4 | 0.3 ± 4.0 | -2.0 ± 3.9 |
| Day 11 | -1.5 ± 5.2 | 6.0 ± 11.1 | -4.0 ± 10.5 |
| Last Visit | -1.5 ± 5.2 | 6.0 ± 11.1 | -3.0 ± 8.7 |
The PANSS consisted of three subscales: a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) and a score of 7 (extremely severe symptoms). The PANSS positive subscale score was the sum of the rating scores for the 7 positive scale items from the PANSS panel. The 7 positive symptom constructs are delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution, and hostility. The PANSS Positive Subscale ranges from 7 (absence of symptoms) to 49 (extremely severe symptoms). Last Visit is the last scheduled post-baseline evaluation including early termination evaluation.
| Units on a scale | Cohort 1 - Brexpiprazole 4mg | Cohort 2- Brexpiprazole 1mg | Cohort 3 Brexpiprazole 4mg |
|---|---|---|---|
| Day 6 | -0.8 ± 1.0 | 0.0 ± 2.0 | -0.8 ± 3.9 |
| Day 11 | 0.5 ± 1.0 | 0.5 ± 6.1 | -2.7 ± 7.5 |
| Last Visit | 0.5 ± 1.0 | 0.5 ± 6.1 | -2.0 ± 6.3 |
The PANSS consisted of three subscales: a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) and a score of 7 (extremely severe symptoms). The PANSS negative subscale score was the sum of the rating scores for the 7 negative scale items from the PANSS panel. The 7 negative symptom constructs: blunted affect, emotional withdrawal, poor rapport, passive apathetic withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation, stereotyped thinking. The PANSS Negative Subscale ranges from 7 (absence of symptoms) to 49 (extremely severe symptoms). Last Visit is the last scheduled post-baseline evaluation including early termination evaluation.
| Units on a scale | Cohort 1 - Brexpiprazole 4mg | Cohort 2- Brexpiprazole 1mg | Cohort 3 Brexpiprazole 4mg |
|---|---|---|---|
| Day 6 | -2.5 ± 4.4 | 1.0 ± 1.0 | 0.3 ± 1.0 |
| Day 11 | -1.5 ± 2.4 | 0.5 ± 3.0 | -0.3 ± 3.2 |
| Last Visit | -1.5 ± 2.4 | 0.5 ± 3.0 | -0.3 ± 2.6 |
The severity of illness for each participant was rated using the CGI-S scale. To assess CGI-S, the study physician answered the following question: "Considering your total clinical experience with this particular population, how mentally ill is the participant at this time?" Response choices included: 0 = not assessed; 1 = normal, not ill at all; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants. Last Visit is the last scheduled post-baseline evaluation including early termination evaluation.
| Units on a scale | Cohort 1 - Brexpiprazole 4mg | Cohort 2- Brexpiprazole 1mg | Cohort 3 Brexpiprazole 4mg |
|---|---|---|---|
| Day 6 | 0.3 ± 0.5 | 0.0 ± 0.0 | 0.8 ± 1.0 |
| Day 11 | 0.5 ± 1.0 | 0.0 ± 0.0 | 1.0 ± 1.0 |
| Last Visit | 0.5 ± 1.0 | 0.0 ± 0.0 | 0.8 ± 1.0 |
The efficacy of trial medication were rated for each participant using the CGI-I scale. The study physician must rate the participant's total improvement whether or not it is due entirely to drug treatment. All responses were compared to the participant's condition at baseline. Response choices include: 0 = not assessed; 1 =very much improved; 2 = much improved; 3 = minimally improved; 4 = no change; 5 =minimally worse; 6 = much worse; and 7 = very much worse. Last Visit is the last scheduled post-baseline evaluation including early termination evaluation.
| Units on a scale | Cohort 1 - Brexpiprazole 4mg | Cohort 2- Brexpiprazole 1mg | Cohort 3 Brexpiprazole 4mg |
|---|---|---|---|
| Day 6 | 4.0 ± 0.0 | 4.0 ± 0.0 | 4.0 ± 0.0 |
| Day 11 | 3.5 ± 1.0 | 3.8 ± 0.5 | 2.7 ± 1.2 |
Collected over Adverse events were reported once the informed consent was signed, throughout the 10-day treatment period until the safety follow-up via telephone 30 (+2) days post-last dose of study medication.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1 - Brexpiprazole 4 mg | — | 0/4 (0%) | 4/4 (100%) |
| Cohort 2 - Brexpiprazole 1 mg | — | 0/4 (0%) | 2/4 (50%) |
| Cohort 3 - Brexpiprazole 4 mg | — | 0/4 (0%) | 3/4 (75%) |
| Event | Cohort 1 - Brexpiprazole 4 mg | Cohort 2 - Brexpiprazole 1 mg | Cohort 3 - Brexpiprazole 4 mg |
|---|---|---|---|
| Abdominal discomfortGastrointestinal disorders | 0/4 | 2/4 | 0/4 |
| BlepharospasmEye disorders | 1/4 | 0/4 | 0/4 |
| Abdominal painGastrointestinal disorders | 1/4 | 0/4 | 0/4 |
| Dental carriesGastrointestinal disorders | 0/4 | 0/4 | 1/4 |
| DyspepsiaGastrointestinal disorders | 1/4 | 0/4 | 1/4 |
| FatigueGeneral disorders | 1/4 | 0/4 | 0/4 |
| MalaiseGeneral disorders | 1/4 | 0/4 | 0/4 |
| Musculoskeletal painMusculoskeletal and connective tissue disorders | 0/4 | 0/4 | 1/4 |
| AkathisiaNervous system disorders | 1/4 | 0/4 | 1/4 |
| SedationNervous system disorders | 1/4 | 0/4 | 0/4 |
| Age, Continuous(Years) | Cohort 1 - Brexpiprazole 4 mg | Cohort 2 - Brexpiprazole 1 mg | Cohort 3 - Brexpiprazole 4 mg | Total |
|---|---|---|---|---|
| Mean | 38.3 ± 4.4 | 40.8 ± 11.9 | 45 ± 6.9 | 41.3 ± 8.1 |
| Sex: Female, Male(Participants) | Cohort 1 - Brexpiprazole 4 mg | Cohort 2 - Brexpiprazole 1 mg | Cohort 3 - Brexpiprazole 4 mg | Total |
|---|---|---|---|---|
| Female | 3 | 1 | 1 | 5 |
| Male | 1 | 3 | 3 | 7 |
The record gives a start of Sep 2013, a primary completion of Jul 2014 and a completion of Aug 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2016, 1 year 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Brexpiprazole
Otsuka Pharmaceutical Development & Commercialization, Inc. →